Brief: Imugene Ltd Announces New Clinical Trial Collaboration And Supply Agreement With MSD
15/03/2022 24:55
March 15 (Reuters) - Imugene Ltd IMU.AX :
* ANNOUNCED NEW CLINICAL TRIAL COLLABORATION AND SUPPLY
AGREEMENT
WITH MSD
* NEXTHERIZON WILL ASSESS HER-VAXX IN COMBINATION WITH
CHEMOTHERAPY OR PEMBROLIZUMAB IN PATIENTS WITH HER-2 POSITIVE
GASTRIC CANCER
* STUDY'S PRIMARY ENDPOINTS ARE SAFETY AND RESPONSE RATE
Source text for Eikon: ID:nASX5GrFxy
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement